Lokavant to Present Next-Generation Causal AI’s Impact on Clinical Trial Feasibility at DPHARM 2024 Innovations Conference
12 September 2024 - 12:37PM
Business Wire
Lokavant, the clinical trial intelligence platform company,
today announced that Aaron Mackey, PhD, Lokavant Senior Vice
President of AI and Development, will be speaking at DPHARM 2024
(Philadelphia, PA) on Tuesday, September 17 at 12:05 pm. Mackey
will highlight the next-generation form of artificial intelligence,
Causal AI, and how it can optimize clinical trial feasibility
assessments and help trial sponsors determine the next best course
of action to keep trials on track to meet key milestones.
Almost 80% of clinical trial feasibility assessments have poor
data collection mechanisms for comprehensive estimates and reliable
forecasts, according to ISR Reports. As a result, trials are slow,
and resources are wasted. Lokavant’s Spectrum™ feasibility software
allows study teams to predict, optimize, and control trial
timelines and costs in real-time, enabling iterative analysis and
mid-study course correction – critical in today’s dynamic,
hyper-complex trials. Spectrum leverages Causal AI to accurately
prescribe recommendations to proactively circumvent problems up
front, as well as continuously throughout trials to adjust for
changes – such as mid-study protocol amendments, which have
increased by 60%, according to a 2022 study.
“Today’s specialized clinical trials demand technology solutions
as smart as the science being studied to overcome long-standing
operational challenges,” said Mackey. “Causal AI is a promising
innovation that will allow trial teams to overcome common hurdles –
such as frequent, mid-study amendments – and drive faster drug
development.”
Lokavant’s Clinical Intelligence Platform and predictive
analytics applications are built with proprietary historical trial
data from more than 2,000 studies involving more than 14,000
investigators, 12,000 healthcare institutions, real-world data
(RWD) sources, and more than 400,000 third-party trials. The
platform enables sponsors and CROs to accurately see real-time
trial performance and feasibility assessments to optimize
decision-making. It has already proven a 70x improvement in
enrollment forecast accuracy and over $1 million in cost savings
from participant retention.
Learn more about the advantages of Causal AI and Lokavant’s
Spectrum solution at DPHARM in Philadelphia on Tuesday, September
17th (12:05-12:35 pm EST).
About Lokavant
Lokavant is reshaping how clinical trial teams execute studies
with its AI-optimized Clinical Intelligence Platform. Spectrum, a
next-generation study feasibility solution, is part of Lokavant’s
Clinical Intelligence Platform and built with proprietary
historical trial data from more than 2,000 studies involving more
than 14,000 investigators, 12,000 healthcare institutions,
real-world data (RWD) sources, and more than 400,000 third-party
trials. With Spectrum, study teams can predict, optimize, and
control trial timelines and costs in real time, enabling iterative
feasibility analysis and mid-study course correction. Lokavant is
on a mission to transform clinical research with AI that augments
people, integrates with processes, and optimizes existing
technologies. Learn more at www.lokavant.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240912286601/en/
Lisa Barbadora, Big Valley for Lokavant +1 (610) 420-3413
lbarbadora@bigvalley.co / lbarbadora@barbadoraink.com